STOK - Stoke Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$43.86
DETAILS
HIGH:
$60.00
LOW:
$35.00
MEDIAN:
$40.00
CONSENSUS:
$43.86
UPSIDE:
49.49%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||
| Revenue | 184.4 | 36.6 | 8.8 | 12.4 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 1.9 | 0.5 | 0.2 | 0.1 |
| Gross Profit | 184.4 | 36.6 | 8.8 | 12.4 | 0 | (1.9) | (0.5) | (0.2) | (0.1) |
| Operating Expenses | |||||||||
| R&D Expenses | 137.9 | 89.1 | 82.2 | 77.8 | 54.2 | 32.2 | 23.3 | 8.4 | 3.6 |
| SG&A Expenses | 67.1 | 48.8 | 41.3 | 38.9 | 31.9 | 20.8 | 11.9 | 4.4 | 2.0 |
| Other Expenses | 0 | 0 | 0 | 0 | 0 | (1.9) | 0 | (0.0) | (0.0) |
| Operating Expenses | 205.0 | 137.9 | 123.6 | 116.8 | 86.1 | 51.1 | 35.2 | 12.8 | 5.6 |
| Operating Income | |||||||||
| Operating Income | (20.6) | (101.4) | (114.8) | (104.4) | (86.1) | (53.0) | (35.7) | (12.8) | (5.6) |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0.1 | 0.7 | 3.4 | 0.3 | 0 |
| Profitability | |||||||||
| EBITDA | (18.8) | (99.2) | (112.3) | (102.8) | (85.1) | (50.3) | (31.9) | (12.6) | (5.4) |
| EBIT | (20.6) | (101.4) | (114.8) | (104.4) | (86.1) | (52.2) | (32.3) | (12.8) | (5.6) |
| Income Before Tax | (6.9) | (89.0) | (104.7) | (101.1) | (85.8) | (52.2) | (32.3) | (12.5) | (5.6) |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (6.9) | (89.0) | (104.7) | (101.1) | (85.8) | (52.2) | (32.3) | (12.5) | (5.6) |
| Per Share Data | |||||||||
| EPS (Basic) | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 | -1.56 | -1.59 | -0.53 | -0.24 |
| EPS (Diluted) | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 | -1.56 | -1.59 | -0.53 | -0.24 |
| Shares Outstanding | 59.2 | 54.0 | 44.0 | 38.9 | 36.7 | 33.5 | 18.0 | 23.5 | 23.5 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Assets | |||||||||
| Cash & Cash Equivalents | 84.2 | 128.0 | 191.4 | 113.6 | 144.9 | 287.3 | 222.5 | 105.4 | 1.8 |
| Short-Term Investments | 200.4 | 88.9 | 10.0 | 116.0 | 74.9 | 0 | 0 | 0 | 0 |
| Net Receivables | 7.9 | 0.7 | 0.1 | 0.6 | 0.1 | 0.0 | 0.3 | 0.2 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 13.1 | 4.0 | 2.6 | 3.0 | 2.3 | 0.2 | 0 | 0 | 0 |
| Total Current Assets | 305.7 | 232.8 | 215.3 | 244.1 | 229.2 | 293.9 | 226.0 | 106.1 | 1.9 |
| Non-Current Assets | |||||||||
| Property, Plant & Equipment | 6.2 | 8.3 | 12.4 | 11.4 | 9.1 | 3.8 | 2.5 | 1.2 | 0.5 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 29.8 | 0 | 0 | 0 | 0 | 0 | 0.2 | 0.1 |
| Other Non-Current Assets | 106.5 | 0.7 | 0.6 | 0.6 | 0.6 | 0.2 | 0.2 | 0 | 0 |
| Total Non-Current Assets | 112.7 | 38.8 | 13.0 | 12.0 | 9.6 | 4.0 | 2.7 | 1.4 | 0.5 |
| Total Assets | 418.4 | 271.6 | 228.3 | 256.1 | 238.9 | 297.9 | 228.8 | 107.5 | 2.4 |
| Current Liabilities | |||||||||
| Account Payables | 4.9 | 2.5 | 1.7 | 0.8 | 2.4 | 1.5 | 0.8 | 1.1 | 0.1 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Deferred Revenue | 11.9 | 19.0 | 15.3 | 14.9 | 0 | 0 | 0 | 0 | (3) |
| Other Current Liabilities | 41.0 | 8.4 | 6.5 | 6.3 | 5.9 | 4.6 | 2.1 | 0 | 0 |
| Total Current Liabilities | 57.9 | 40.1 | 30.8 | 31.4 | 17.1 | 11.4 | 4.1 | 2.5 | 3.7 |
| Non-Current Liabilities | |||||||||
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 8.1 | 2.5 | 4.9 | 3.0 | 3.9 | 0.4 | 0.2 | 0.0 | 0.0 |
| Total Non-Current Liabilities | 8.1 | 2.5 | 38.0 | 39.8 | 3.9 | 0.4 | 0.2 | 0.0 | 0.0 |
| Total Liabilities | 66.0 | 42.5 | 68.8 | 71.2 | 21.1 | 11.8 | 4.3 | 2.5 | 3.7 |
| Stockholders' Equity | |||||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Retained Earnings | (497.7) | (490.8) | (401.8) | (297.1) | (196.1) | (110.3) | (58.0) | (25.7) | (13.2) |
| Accumulated Other Comprehensive Income | 0.5 | (0.2) | (0.0) | (1.2) | (0.2) | 0 | 0 | (0.4) | (0.2) |
| Total Stockholders' Equity | 352.5 | 229.0 | 159.6 | 184.8 | 217.8 | 286.1 | 224.4 | 105.1 | (1.3) |
| Total Liabilities & Equity | 418.4 | 271.6 | 228.3 | 256.1 | 238.9 | 297.9 | 228.8 | 107.5 | 2.4 |
| Debt Metrics | |||||||||
| Total Debt | 0 | 2.3 | 2.1 | 2.4 | 1.5 | 1.1 | 0 | 0 | 3 |
| Net Debt | (84.2) | (125.7) | (189.4) | (111.2) | (143.4) | (286.2) | (222.5) | (105.4) | 1.2 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Net Income | (6.9) | (89.0) | (104.7) | (101.1) | (85.8) | (52.2) | (32.3) | (12.5) | (5.6) |
| Depreciation & Amortization | 1.8 | 2.2 | 2.5 | 1.5 | 1.0 | 0.9 | 0.5 | 0.2 | 0.1 |
| Stock-Based Compensation | 32.2 | 27.5 | 25.3 | 22.9 | 16.4 | 5.8 | 1.9 | 0.2 | 0.0 |
| Change in Working Capital | 16.3 | (28.1) | (6.0) | 43.0 | 0.0 | 2.3 | (1.1) | 1.1 | 0.0 |
| Other Non-Cash Items | 2.1 | 0.6 | 1.9 | 1.8 | 1.3 | 1.0 | 0.0 | 0.0 | 0.0 |
| Operating Cash Flow | 45.6 | (86.9) | (81.1) | (31.9) | (66.9) | (42.2) | (31.1) | (11.0) | (5.4) |
| Investing Activities | |||||||||
| Capital Expenditure | (0.7) | (0.2) | (1.6) | (4.0) | (1.2) | (1.1) | (1.6) | (0.9) | (0.1) |
| Acquisitions | 0 | 0 | 0 | 45.3 | 75.2 | 0 | 0.0 | 0.0 | 0 |
| Purchases of Investments | (322.7) | (167.3) | 0 | (201.3) | (87.2) | 0 | 0 | 0 | 0 |
| Sales/Maturities of Investments | 136.6 | 60 | 107.6 | 159.4 | 12 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (45.3) | (75.2) | 0 | 0 | 0.0 | 0 |
| Investing Cash Flow | (186.8) | (107.5) | 105.9 | (45.9) | (76.4) | (1.1) | (1.6) | (0.9) | (0.1) |
| Financing Activities | |||||||||
| Net Debt Issuance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 2.3 | 0.9 | 1.1 | (0.0) | 2.7 | (2.1) | (0.4) | 3.0 |
| Financing Cash Flow | 97.4 | 131.1 | 53.0 | 46.4 | 1.3 | 108.1 | 149.8 | 115.6 | 6.0 |
| Cash Position | |||||||||
| Net Change in Cash | (43.8) | (63.2) | 77.9 | (31.3) | (142.0) | 64.8 | 117.1 | 103.8 | 0.5 |
| Cash at Beginning | 128.8 | 192.0 | 114.1 | 145.5 | 287.5 | 222.7 | 105.6 | 1.9 | 1.4 |
| Cash at End | 84.9 | 128.8 | 192.0 | 114.1 | 145.5 | 287.5 | 222.7 | 105.6 | 1.9 |
| Free Cash Flow | 44.9 | (87.1) | (82.7) | (35.8) | (68.1) | (43.3) | (32.7) | (11.9) | (5.5) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 184.4 | 36.6 | 8.8 | 12.4 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 184.4 | 36.6 | 8.8 | 12.4 | 0 | (1.9) | (0.5) | (0.2) | (0.1) |
| Operating Income | (20.6) | (101.4) | (114.8) | (104.4) | (86.1) | (53.0) | (35.7) | (12.8) | (5.6) |
| Net Income | (6.9) | (89.0) | (104.7) | (101.1) | (85.8) | (52.2) | (32.3) | (12.5) | (5.6) |
| EPS (Diluted) | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 | -1.56 | -1.59 | -0.53 | -0.24 |
| Balance Sheet | |||||||||
| Cash & Equivalents | 84.2 | 128.0 | 191.4 | 113.6 | 144.9 | 287.3 | 222.5 | 105.4 | 1.8 |
| Total Assets | 418.4 | 271.6 | 228.3 | 256.1 | 238.9 | 297.9 | 228.8 | 107.5 | 2.4 |
| Total Debt | 0 | 2.3 | 2.1 | 2.4 | 1.5 | 1.1 | 0 | 0 | 3 |
| Stockholders' Equity | 352.5 | 229.0 | 159.6 | 184.8 | 217.8 | 286.1 | 224.4 | 105.1 | (1.3) |
| Cash Flow | |||||||||
| Operating Cash Flow | 45.6 | (86.9) | (81.1) | (31.9) | (66.9) | (42.2) | (31.1) | (11.0) | (5.4) |
| Capital Expenditure | (0.7) | (0.2) | (1.6) | (4.0) | (1.2) | (1.1) | (1.6) | (0.9) | (0.1) |
| Free Cash Flow | 44.9 | (87.1) | (82.7) | (35.8) | (68.1) | (43.3) | (32.7) | (11.9) | (5.5) |